Program
lerodalcibep
Also written as “Lerodalcibep”, “LIB003” and “lerodalcibep 300 mg Monthly SC”.
Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Cardiovascular Diseases · Myocardial Infarction · Homozygous Familial Hypercholesterolemia, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LIB Therapeutics | 125 open or running | phase 3since Jul 22, 2019 | May 22, 2018 | Jul 31, 2028phase 3 · NCT07102511 |
| Hasten Biopharmaceutical | 22 open or running | phase 3since Aug 21, 2024 | Jul 2, 2024 | none ahead |
Also a collaborator on its studies: medpace-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 22, 2018First study: phase 2 study in LDL CholesterolNew to LIB TherapeuticsLIB Therapeutics · NCT03549260 · 81 enrolled · United States
- Feb 14, 2019Phase 2 study in HypercholesterolemiaLIB Therapeutics · NCT03847974 · 32 enrolled · United States
- Jul 22, 2019Phase 3 study in Homozygous Familial HypercholesterolemiaLIB Therapeutics · NCT04034485 · 65 enrolled · United States, India, Israel and more
- Mar 6, 20215 phase 3 studiesLIB Therapeutics · NCT04790513, NCT04798430, NCT04797104 and 2 more
- Aug 6, 2021Phase 3 study in HypercholesterolemiaLIB Therapeutics · NCT05004675 · 166 enrolled · France, Germany, Norway and more
- Jan 17, 2022Phase 3 study in HypercholesterolemiaLIB Therapeutics · NCT05234775 · 22 enrolled · United States
- Jul 2, 2024Hasten Biopharmaceutical's first study: phase 1 study in HypercholesterolemiaNew to Hasten BiopharmaceuticalHasten Biopharmaceutical · NCT06504043 · 30 planned · China
- Aug 21, 2024Phase 3 study in HypercholesterolemiaHasten Biopharmaceutical · NCT06568471 · 210 planned · China
- Jul 28, 2025Phase 3 study in HypercholesterolemiaLIB Therapeutics · NCT07102511 · 150 planned · United States, Israel, New Zealand and more
- Aug 16, 2026Phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)LIB Therapeutics · NCT07775339 · 150 planned · India, Israel, New Zealand and more
Ahead
- Jul 31, 2028Primary completion: phase 3 study in HypercholesterolemiaLIB Therapeutics · NCT07102511
- Jul 31, 2031Primary completion: phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)LIB Therapeutics · NCT07775339
TargetBeta
“Subtilisin/kexin type 9 inhibitor”ChEMBL 37, by rule
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| inclisiranrule | Novartis | phase 4 | 37 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07775339Heterozygous Familial Hypercholesterolemia (HeFH) · India, Israel, New Zealand and more | 3 | Not yet recruiting | LIB Therapeutics | Jul 31, 2031 | 150 |
| NCT07102511Hypercholesterolemia · United States, Israel, New Zealand and more | 3 | By invitation | LIB Therapeutics | Jul 31, 2028 | 150 |
| NCT06568471Hypercholesterolemia · China | 3 | Recruiting | Hasten Biopharmaceutical | Feb 2026 | 210 |
| NCT06504043Hypercholesterolemia · China | 1 | By invitation | Hasten Biopharmaceutical | Jan 8, 2025 | 30 |
| NCT05234775Hypercholesterolemia · United States | 3 | Completed | LIB Therapeutics | Jun 30, 2022 | 22 |
| NCT05004675Hypercholesterolemia · France, Germany, Norway and more | 3 | Completed | LIB Therapeutics | May 30, 2024 | 166 |
| NCT04806893Cardiovascular Diseases · United States, India, Israel | 3 | Active, not recruiting | LIB Therapeutics | Nov 15, 2023 | 900 |
| NCT04797247Cardiovascular Diseases · United States | 3 | Active, not recruiting | LIB Therapeutics | Nov 15, 2023 | 900 |
| NCT04797104Heterozygous Familial Hypercholesterolemia · United States, Israel, Norway and more | 3 | Completed | LIB Therapeutics | Jul 30, 2023 | 478 |
| NCT04798430Hypercholesterolemia · United States, India, Israel and more | 3 | By invitation | LIB Therapeutics | Jul 30, 2025 | 2,000 |
| NCT04790513Hypercholesterolemia · United States | 3 | Completed | LIB Therapeutics | Sep 30, 2022 | 204 |
| NCT04034485Homozygous Familial Hypercholesterolemia · United States, India, Israel and more | 3 | Completed | LIB Therapeutics | Sep 12, 2022 | 65 |
| NCT03847974Hypercholesterolemia · United States | 2 | Completed | LIB Therapeutics | Apr 7, 2020 | 32 |
| NCT03549260LDL Cholesterol · United States | 2 | Completed | LIB Therapeutics | Nov 9, 2018 | 81 |
How it is read
Names in the registry
- “lerodalcibep”, 8 entries
- “Lerodalcibep”, 2 entries
- “LIB003”, 2 entries
- “lerodalcibep 300 mg Monthly SC”, 1 entry
- “HST101”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 8 studies
- Hyperlipoproteinemia Type II, 2 studies
- Cardiovascular Diseases, 1 study
- Myocardial Infarction, 1 study
- Homozygous Familial Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.